
1. target oncol. 2016 aug;11(4):469-77. doi: 10.1007/s11523-016-0421-1.

immunotherapy gastric cancer: focus immune checkpoints.

alsina m(1)(2)(3), moehler m(4), hierro c(5)(6), guardeño r(7), tabernero
j(5)(6).

author information: 
(1)oncology deparment, vall d'hebron university hospital- universitat autònoma de
barcelona (uab), barcelona, spain. malsinamaqueda@gmail.com.
(2)oncology deparment, vall d'hebron institute oncology (vhio), barcelona,
spain. malsinamaqueda@gmail.com.
(3)vall d'hebron university hospital, pg. vall d'hebron 119-129, 08035,
barcelona, spain. malsinamaqueda@gmail.com.
(4)first department internal medicine, johannes gutenberg-university mainz,
mainz, germany.
(5)oncology deparment, vall d'hebron university hospital- universitat autònoma de
barcelona (uab), barcelona, spain.
(6)oncology deparment, vall d'hebron institute oncology (vhio), barcelona,
spain.
(7)oncology deparment, hospital universitari doctor josep trueta, girona, spain.

gastric cancer (gc) major world-wide health problem. third leading
cause death cancer. treatment advanced gc chemotherapy has
limited efficacy. addition targeted therapies like trastuzumab and
ramucirumab added modest benefit, human epidermal growth
factor receptor 2 (erbb2 her2)-positive patients second-line
setting, respectively. development new effective therapeutic
strategies must consider genetic complexity heterogeneity gc;
prognostic predictive biomarkers identified clinical
implementation. immune deregulation associated gc subtypes,
especially associated virus infection high
mutational rate. different mechanisms prevent immunologic escape been
characterized last years; particular pd-1/pd-l1 inhibitors
pembrolizumab, avelumab, durvalumab atezolizumab shown early sign of
efficacy. therefore, immunotherapeutic strategies may provide new opportunities
for gc patients. review discuss (1) main characteristics gc
treatment, (2) immune response gc, (3) current status of
immune-related strategies clinical development gc patients, focusing on
immune checkpoints therapies.

doi: 10.1007/s11523-016-0421-1 
pmid: 26880697  [indexed medline]

